Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 2.12B +186.3% |
| Revenue (ttm) | 66.09M +45.0% |
| Net Income | -394.60M |
| EPS | -3.52 |
| Shares Out | 139.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,427,239 |
| Open | 14.87 |
| Previous Close | 14.55 |
| Day's Range | 14.43 - 16.73 |
| 52-Week Range | 7.95 - 28.25 |
| Beta | 1.81 |
| Analysts | Buy |
| Price Target | 26.63 (+75.2%) |
| Earnings Date | Aug 6, 2026 |
About NTLA
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $26.63, which is an increase of 75.20% from the latest price.
News
Intellia Therapeutics rises 12.9%
Intellia Therapeutics (NTLA) is up 12.9%, or $1.88 to $16.43.
Intellia Therapeutics rises 10.7%
Intellia Therapeutics (NTLA) is up 10.7%, or $1.56 to $16.11.
Intellia Therapeutics presents additional results from Phase 3 HAELO trial
Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, HAE, in a late-breaking oral presentation at the E...
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No questions were raised by stockholders during the session.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Phase III data show a single infusion yields 87% attack reduction and eliminates long-term prophylaxis in HAE, with a strong safety profile and broad patient benefit. Rolling BLA submission is underway, targeting a 2027 U.S. launch, while commercialization and education efforts ramp up.
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Significant progress was highlighted, including completion of the first phase III in vivo CRISPR trial and strong HAE data showing most patients free of disease after one treatment. Rolling BLA submissions are underway, and TTR programs are advancing with new safety protocols and global enrollment.
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
Bernstein raised the firm’s price target on Intellia Therapeutics (NTLA) to $17 from $13 and keeps a Market Perform rating on the shares. Biotech has had a strong start to…
Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent…
Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Phase III HAELO study showed 87% attack rate reduction and 62% of patients attack and therapy free, with commercialization of lonvo-z targeted for next year. TTR program is progressing post-clinical hold, and strong payer interest supports a premium pricing strategy.
Intellia Therapeutics price target lowered to $19 from $20 at BofA
BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated operating expense trends and share…
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $49 from $58 and keeps a Buy rating on the shares. The firm said its 1Q26 report was largely…
Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
Reports Q1 revenue $15.05M, consensus $13.81M. “It has been a remarkable start to 2026 for Intellia,” said John Leonard, Intellia President and Chief Executive Officer. “With lonvo-z, we achieved a…
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Intellia Therapeutics Earnings release: Q1 2026
Intellia Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Intellia Therapeutics Quarterly report: Q1 2026
Intellia Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an...
Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today
20:06 EDT Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics Proxy statement: Proxy filing
Intellia Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Intellia Therapeutics Proxy statement: Proxy filing
Intellia Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today
23:21 EDT Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics (NTLA) today
Intellia Therapeutics 16.7M share Secondary priced at $10.75
The deal size was increased to $180M in common stock from $150M in common stock. Jefferies, Goldman Sachs and Citi acted as joint book running managers for the offering. Published…
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...